Selexis SA executes commercial licence agreements with Turgut Pharmaceuticals

Feb 26, 2019

Selexis SA announces it has executed two commercial licence agreements with Turgut Pharmaceuticals for the development of biosimilar antibodies. This expansion of the partnership between the two companies aims to develop a biosimilar for the treatment of metastatic HER2-positive cancer and a checkpoint inhibitor for certain cancers.

Print Page Mail Article